CPAY

Corpay, Inc.

$408.36

+1.44% 2026-10-20

FinancialsS&P 500

1M 3M 6M 1Y 2Y

CPAYSPY

+2.3%

+2.7%

+11.5%

+23.8%

YTD

+35.7%

+42.8%

Live chart

Loading live chart…

Grades vs sector

Momentum

93rd pct in sector

12-1 return: +49.3%
Percentile within its GICS sector across the S&P 1500.

Growth

75th pct in sector

B+

Revenue growth (YoY): +21.5%
Percentile within its GICS sector across the S&P 1500.

Value

34th pct in sector

C-

Forward E/P: 7.9% · EBITDA/EV: 8.2%
Percentile within its GICS sector across the S&P 1500.

Profitability

66th pct in sector

Profit margin: +22.7% · Return on equity: +29.2%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Top 15

rank 93 of 499 · 12-1 momentum % 40.4

Momentum Blend

not in the current book

New Highs Growth

not ranked (outside this model's universe or screens)

Conviction 20

not in the current book

News

More news

Canadian Dollar Weakens as October Rate Hike Expectations Ease, Corpay Says

MT Newswires · Oct 19

Corpay MAAnnouncement: Volatus Aerospace Targets AISPECO in $13M Aerial Tech Deal

MarketBeat · Oct 16

Will Corpay (CPAY) Beat Estimates Again in Its Next Earnings Report?

Zacks · Oct 14

1 Growth Stock with Explosive Upside and 2 We Avoid

StockStory · Oct 12

2 Financials Stocks Worth Your Attention and 1 We Find Risky

StockStory · Oct 09

Key stats

Market cap$26.8B

P/E (trailing)24.8

P/E (forward)12.9

52-week range252.84 – 427.46

Revenue growth (YoY, latest qtr)+21.5%

Dividend yield0.00%

Analyst consensusBuy (15)

Mean price target$461.00 (+13%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Roughly fairly valued

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

▲DCF (base case)above the price by 65%

▼Forward P/E vs sector12.9x vs median 10.2x

•Piotroski F-score5/9

▼Net debt / EBITDA4.5x

•Analyst target+13% (15 analysts)

Discounted cash flow

Bear

$311

-24%

growth 9% · disc. 9.7% · term. 2.0%

Base

$674

+65%

growth 16% · disc. 8.7% · term. 2.5%

Bull

$1,218

+198%

growth 20% · disc. 7.7% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 7% a year for 10 years.

Implied

+7%/yr

FCF, last 3 yrs

+29%/yr

FCF, last 5 yrs

-1%/yr

Revenue, last 3 yrs

+10%/yr

Revenue, last 5 yrs

+14%/yr

Same inputs as the DCF above: trailing free cash flow 1.6B, 8.7% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.89 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Financials

P/E (trailing)

sector median 13.0× · 85th pct

24.8×
pricier

Forward P/E

sector median 10.2× · 75th pct

12.9×
pricier

EV / EBITDA

sector median 10.9× · 72nd pct

14.7×
pricier

Price / sales

sector median 2.8× · 76th pct

5.3×
pricier

Price / book

sector median 1.6× · 95th pct

7.6×
pricier

FCF yield

sector median 8.2% · 34th pct

6.1%
pricier

Forward EPS $31.57 vs trailing $16.45 (+92% expected growth). Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

–

Operating margin

43.7%

FCF margin

32.6%

Net margin

22.7%

Return on equity

32.2%

Return on invested capital

9.7%

Net debt / EBITDA

4.5×

Current ratio

1.0×

Interest cover

5.0×

Cash conversion (OCF/NI)

1.6×

Piotroski F-score 5/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved

Analysts

Mean target

$461

+13%

Analysts

Buy

Range

$390–$536

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$4.5B	$1.1B	$1.3B
2024	$4.0B	$1.0B	$1.8B
2023	$3.8B	$981.9M	$1.9B
2022	$3.4B	$954.3M	$603.4M
2021	$2.8B	$839.5M	$1.1B
2020	$2.4B	$704.2M	$1.4B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +9.7%.

Earnings

Next report: 2026-11-04 · during market · EPS est 7.20

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-05	6.58	7.00	+6.3%
2026-05-07	5.47	5.80	+6.0%
2026-02-04	5.94	6.04	+1.7%
2025-11-05	5.64	5.70	+1.0%
2025-08-06	5.12	5.13	+0.1%
2025-05-06	4.51	4.51	-0.1%
2025-02-05	5.35	5.36	+0.2%
2024-11-07	4.97	5.00	+0.5%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$1.3B	+21.5%
2026-03-31	$1.3B	–
2025-12-31	$1.2B	–
2025-09-30	$1.2B	–
2025-06-30	$1.1B	–

Analyst actions

Scotiabank

2026-09-02 · init

→ Sector Outperform
PT $536

RBC Capital

2026-08-31 · main

Sector Perform → Sector Perform
PT $438

Wolfe Research

2026-08-25 · main

Outperform → Outperform
PT $530

Cantor Fitzgerald

2026-08-10 · main

Overweight → Overweight
PT $480

JP Morgan

2026-08-06 · main

Overweight → Overweight
PT $470

UBS

2026-08-06 · main

Neutral → Neutral
PT $415

Insider trades

Clarke Ronald